Lantern Pharma Expands Clinical Leadership Team

Lantern Pharma, Inc. a clinical stage biopharmaceutical company using its proprietary RADR artificial intelligence (AI) and machine learning (ML) platform to transform the cost, pace, and timeline of oncology drug discovery and development, expanded its clinical development team with the addition of Reggie Ewesuedo as vice president of clinical development, and several additional team members.

The expansion of the clinical development team will continue to advance the Harmonic Trial, a Phase 2 trial for never smokers with non-small cell lung cancer (NSCLC), as well as the upcoming first-in-human Phase 1 clinical trials for Lantern’s drug candidates LP-184 and LP-284, which are both anticipated to launch in mid-2023.

“We are looking forward to the many contributions that Dr. Ewesuedo and our expanded clinical development team will bring to Lantern and our clinical programs,” said Panna Sharma, Lantern’s President and CEO. “They are joining Lantern at a pivotal period in our company’s growth as we advance our drug candidates into and through clinical trials. I am confident in the decades of proven experience of our new team members and their ability to progress Lantern’s drug candidates to improve the lives of cancer patients,” continued Sharma.

Ewesuedo has more than 20 years of experience in preclinical, early, and late phase drug development including roles in clinical development leadership at AstraZeneca and Pfizer.

Lantern also appointed Ernest Kitt as head of clinical operations. Kitt has racked up more than 20 years of experience in oncology drug development and clinical operations with proven success in bringing drugs to market. He has held clinical oncology leadership positions at companies including Amgen/Onyx, Aptose, and Biosplice.

New clinical development team members also include Annum Zhara as a Senior Clinical Trial Project Manager and Brianna MacCrory as a Clinical Trial Navigator.